Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04079010 · ClinicalTrials.gov registry record · NA
The Effect of Blood Flow Restriction With and Without Arginine on Physical Performance and Growth Hormone
A NA study of Blood Flow Restriction and Growth Hormone, sponsored by University of Mary Hardin-Baylor.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT04079010: Completed NA study of Blood Flow Restriction and Growth Hormone, sponsored by University of Mary Hardin-Baylor.
NCT04079010 is a NA study of Blood Flow Restriction and Growth Hormone that has completed, run by University of Mary Hardin-Baylor. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04079010, a NA study of Blood Flow Restriction and Growth Hormone, has completed, sponsored by University of Mary Hardin-Baylor.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The current study will investigate the effects of Blood Flow Restriction (BFR) training and L-arginine supplementation on recreationally trained female participants. In particular, it will compare performance outcomes and blood markers among two intervention groups (BFR and BFR+Arg) and a control group (CON).
Primary Outcome
1 RM (rep-max) will be utilized to measure lower extremity strength
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Arginine
- PROCEDURE BFR
- DIETARY_SUPPLEMENT Placebo Pill
Study Locations (1)
Texas
- University of Mary Hardin-Baylor - Belton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2019-09-04 |
| Est. Completion | 2019-11-25 |
| Phase | NA |
What the finished NCT04079010 record still lists
NCT04079010 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 4 conditions, with Blood Flow Restriction appearing as the primary indexed condition, and to 3 interventions - of which Arginine is the first listed.
NCT04079010 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT04079010 about?
NCT04079010 is a clinical study titled "The Effect of Blood Flow Restriction With and Without Arginine on Physical Performance and Growth Hormone". The current study will investigate the effects of Blood Flow Restriction (BFR) training and L-arginine supplementation on recreationally trained female participants. In particular, it will compare performance outcomes and blood markers among two intervention groups (BFR and BFR+Arg) and a control gr...
What is the current status of trial NCT04079010?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2019-09-04. Estimated completion is 2019-11-25.
What conditions does trial NCT04079010 study?
This clinical trial studies the following conditions: Blood Flow Restriction, Growth Hormone, Strength Outcomes, Arginine.
What interventions are being tested in trial NCT04079010?
The interventions under investigation include: Arginine (DIETARY_SUPPLEMENT), BFR (PROCEDURE), Placebo Pill (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT04079010?
This trial is sponsored by University of Mary Hardin-Baylor, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04079010 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Blood Flow Restriction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04079010's enrollment target sits among peer trials
30 1593rd of 2000 higher than 299 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI